Isn't FDA a factor in delay rather than throughput?
> If investment costs/risk aren't limiting abundant new drugs, what is?
If we had lots of new drugs available for testing in the first place, they would still require the 6y minimum of trials, then a few years for approval. So FDA doesn't really sound like a good reason to single out.
> If investment costs/risk aren't limiting abundant new drugs, what is?
If we had lots of new drugs available for testing in the first place, they would still require the 6y minimum of trials, then a few years for approval. So FDA doesn't really sound like a good reason to single out.